Tagged with ACA

USA Catherine Owen Adams, CEO of Acadia Pharmaceuticals, discusses how the company’s dual commercial pillars in Parkinson’s disease psychosis and Rett syndrome are delivering much-needed impact for patients with significant unmet needs and shaping Acadia’s next phase of growth. She shares insights into the company’s expansion plans, pipeline strategy, partnership goals,…

Taiwan Professor Pan Chyr Yang is a clinician-scientist with an MD and PhD in pulmonary medicine, holding joint appointments at Academia Sinica and former university leadership roles in National Taiwan University. Recognised for pioneering non-smoker lung cancer screening methodologies in Asia, he has established national surveillance programmes now adopted across the region.…

France Serge Picaud, the Executive Director of the Paris Vision Institute outlines a bold vision to transform ophthalmology through cutting-edge research and innovation. From pioneering the first successful optogenetic vision restoration to advancing therapies for AMD, myopia, and diabetic retinopathy, the institute blends academic excellence with commercial impact supported by 15…

France Professor Bana Jabri, Director of the Institut Imagine, brings a transatlantic perspective to advancing genetic medicine. After 25 years in the US, she now leads efforts in France to harness genomic technologies, foster interdisciplinary collaboration, and modernise academic–industry partnerships. Her vision calls for strategic investment, institutional autonomy, and greater risk…

Switzerland Prof. Andrea Alimonti, Director of the Institute of Oncology Research in Bellinzona, a leading Swiss centre focused on translational cancer research, shares his international journey from Rome to New York , Boston, and now Ticino, where he leads a growing, high-impact research institute. Under his leadership, IOR is expanding with…

Switzerland Antoine Geissbühler wears many hats—physician, academic, innovator, and institutional leader—and is at the forefront of digital transformation in healthcare. In this wide-ranging conversation, the Dean of the Faculty of Medicine at the University of Geneva and President of the BioAlps Association shares his journey, insights into Geneva’s unique life sciences…

UK A roundup of top stories from UK pharma and healthcare, including the innovative manufacturing fund comprised in the government’s new life-sciences-focused budget; GSK’s autoimmune therapy deal with Chimagen Biosciences; Northern Ireland’s potential post-Brexit drug shortages, and Oxford Biomedica’s reband as OXB.   UK to create world-first ‘early warning system’ for…

Hong Kong Yuko Mizuma, general manager of Hong Kong and Macau at Eli Lilly Asia, Inc., shares her impressions of Hong Kong’s healthcare ecosystem after working in Japan and the US, discusses the local impact of obesity, which affects 33 percent of the population, and the positive reimbursement outlook for newer treatments…

Hong Kong Roche has a strong presence in Hong Kong with a local footprint dating back to 1971. Diana Liu, general manager of the Swiss pharma’s Hong Kong & Macau affiliate, outlines its growing local clinical research commitment, one that has seen its clinical trial activities increase 2.5 times and reach an…

Hong Kong Industry veteran Krish Sundaresan, GM for Hong Kong & Macau at Pfizer for the past two and a half years, shares his experience navigating the shifting dynamics brought on by the COVID-19 pandemic, enhancing omni-channel capabilities, and launching four new products in 2023 alone. Sundaresen also discusses the opportunity to…

Hong Kong Tony Cheng, managing director and general manager for Hong Kong & Macau at Merck Healthcare walks us through the challenges and opportunities arising from Hong Kong’s transformation, Merck’s strong local presence, its collaboration with the Hong Kong Science and Technology Park to support local start-ups, the affiliate’s engagement in the…

Switzerland The biggest pharma news from Switzerland, including the industry’s cautious reaction to a new free trade deal with India; the drop in Roche’s share prices; Novartis’ acquisiton of MorphoSys, and the licence agreement between EraCal Therapeutics and Novo Nordisk.   Swiss industry welcomes agreement with India, pharma more cautious (Le…